Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study
Cetrorelix and ganirelix demonstrate comparable live birth rates and embryo quality, yet exhibit distinct safety profiles. Cetrorelix provides superior LH surge suppression and reduced OHSS risk, making it preferable for high-risk patients, while ganirelix may serve cases requiring rapid LH control. Cetrorelix offering enhanced endometrial receptivity (66.2% Type A morphology) and safety advantages. These findings support cetrorelix's role in optimizing ART safety without compromising efficacy.
Authors
- Yingxing Li (ORCID: https://orcid.org/0000-0002-8984-9136)
- Xingyu Lv
- Yi Zhang (ORCID: https://orcid.org/0000-0003-3641-0629)
- Yuan Li (ORCID: https://orcid.org/0000-0002-1683-6801)
- Penghao Li (ORCID: https://orcid.org/0000-0003-2866-539X)
- Xinyue Peng (ORCID: https://orcid.org/0000-0001-6386-2140)
- Yu‐Ling Hu
Institutions
- Chengdu Women's and Children's Central Hospital (CN)
- Second Affiliated Hospital of Chengdu University of Traditional Chinese (CN)
Publication Details
- Journal
- Frontiers in Reproductive Health
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/frph.2025.1492441
- Citations
- 1
- Primary Topic
- Ovarian function and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.70